PTO/SB/17 (10-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


# FEE TRANSMITTAL for FY 2005

*Effective 10/01/2004. Patent fees are subject to annual revision.*

☐ Applicant claims small entity status. See 37 CFR 1.27

**TOTAL AMOUNT OF PAYMENT** ($) 180

| *Complete if Known* | |
|---|---|
| Application Number | 09/633,034 |
| Filing Date | August 4, 2000 |
| First Named Inventor | Tsang, et al. |
| Examiner Name | L.R. Helms |
| Art Unit | 1642 |
| Attorney Docket No. | 072771.0106 |

## METHOD OF PAYMENT *(check all that apply)*

☑ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☐ Deposit Account:

Deposit Account Number: 02-4377

Deposit Account Name: Baker Botts L.L.P.

**The Director is authorized to:** *(check all that apply)*

☐ Charge fee(s) indicated below ☑ Credit any overpayments

☑ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, **except for the filing fee** to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

| Large Entity Fee Code | Large Entity Fee | Small Entity Fee Code | Small Entity Fee | Fee Description | Fee Paid |
|---|---|---|---|---|---|
| 1001 | | 2001 | | Utility filing fee | |
| 1002 | | 2002 | | Design filing fee | |
| 1003 | | 2003 | | Plant filing fee | |
| 1004 | | 2004 | | Reissue filing fee | |
| 1005 | | 2005 | | Provisional filing fee | |

**SUBTOTAL (1)** ($) 0

### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

| | | Extra Claims | | Fee from below | Fee Paid |
|---|---|---|---|---|---|
| Total Claims | -20 = | | X | | =0 |
| Independent Claims | -3 = | | X | | =0 |
| Multiple Dependent | | | | | =0 |

| Large Entity Fee Code | Small Entity Fee Code | Fee Description |
|---|---|---|
| 1202 | 2202 | Claims in excess of 20 |
| 1201 | 2201 | Independent claims in excess of 3 |
| 1203 | 2203 | Multiple dependent claim, if not paid |
| 1204 | 2204 | ** Reissue independent claims over original patent |
| 1205 | 2205 | ** Reissue claims in excess of 20 and over original patent |

**SUBTOTAL (2)** ($) 0

***or number previously paid, if greater; For Reissues, see above*

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

| Large Entity Fee Code | Small Entity Fee Code | Fee Description | Fee Paid |
|---|---|---|---|
| 1051 | 2051 | Surcharge - late filing fee or oath | |
| 1052 | 2052 | Surcharge - late provisional filing fee or cover sheet | |
| 1053 | 1053 | Non-English specification | |
| 1812 | 1812 | For filing a request for *ex parte* reexamination | |
| 1804 | 1804 | Requesting publication of SIR prior to Examiner action | |
| 1805 | 1805 | Requesting publication of SIR after Examiner action | |
| 1251 | 2251 | Extension for reply within first month | |
| 1252 | 2252 | Extension for reply within second month | |
| 1253 | 2253 | Extension for reply within third month | |
| 1254 | 2254 | Extension for reply within fourth month | |
| 1255 | 2255 | Extension for reply within fifth month | |
| 1401 | 2401 | Notice of Appeal | |
| 1402 | 2402 | Filing a brief in support of an appeal | |
| 1403 | 2403 | Request for oral hearing | |
| 1451 | 1451 | Petition to institute a public use proceeding | |
| 1452 | 2452 | Petition to revive - unavoidable | |
| 1453 | 2453 | Petition to revive - unintentional | |
| 1501 | 2501 | Utility issue fee (or reissue) | |
| 1502 | 2502 | Design issue fee | |
| 1503 | 2503 | Plant issue fee | |
| 1460 | 1460 | Petitions to the Commissioner | |
| 1807 | 1807 | Processing fee under 37 CFR 1.17(q) | |
| 1806 | 1806 | Submission of Information Disclosure Stmt | 180 |
| 8021 | 8021 | Recording each patent assignment per property (times number of properties) | |
| 1809 | 2809 | Filing a submission after final rejection (37 CFR 1.129(a)) | |
| 1810 | 2810 | For each additional invention to be examined (37 CFR 1.129(b)) | |
| 1801 | 2801 | Request for Continued Examination (RCE) | |
| 1802 | 1802 | Request for expedited examination of a design application | |

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

**SUBTOTAL (3)** ($) 180

| SUBMITTED BY | | | | (Complete *(if applicable)*) | |
|---|---|---|---|---|---|
| *Name (Print/Type)* | Lisa B. Kole | *Registration No. (Attorney/Agent)* | 35,225 | *Telephone* | 212-408-2500 |
| *Signature* | | | | *Date* | 08/10/2005 |

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Tsang et al.

Serial No.: 09/633,034 Examiner: Helms, L.R.

Filed : August 4, 2000 Group Art Unit: 1642

For : MONOCLONAL ANTIBODIES AGAINST HUMAN COLON CARCINOMA-ASSOCIATED ANTIGENS AND USES THEREFOR

## INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited on August 10 2005 with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450

08/12/2005 HTECKLU1 00000013 09633034
01 FC:1806 180.00 OP

Lisa B. Kole — Attorney Name

35,225 — PTO Registration No.



Signature

August 10 2005 — Date of Signature

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§1.97 and 1.98, applicants respectfully request that the document listed below be considered by the Examiner and made of record in the above-referenced application.

| Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office | Atty. Docket No. A33081-R 072771.0106 | Serial No. 09/633,034 |
|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** (Use several sheets if necessary) | Applicant Tsang *et al.* | |
| | Filing Date August 4, 2000 | Group 1642 |
| | Examiner Helms, L.R. | |

## U.S. PATENT DOCUMENTS

| *Exam. Initial. | No. | | Document No. | Date | Name | Class | Subclass | Filing Date if Approximate. |
|---|---|---|---|---|---|---|---|---|
| | 11 | | 6,346,249 | February 12, 2002 | Barbas III et al. | | | 4/4/2000. |
| | 12 | | 6,342,587 | January 29, 2002 | Barbas III et al. | | | 10/22/1999 |
| | 28 | | 5,958,412 | Sept. 28, 1999 | Welt et al. | | | 6/4/1997 |
| | 33 | | 5,712,369 | January 27, 1998 | Welt et al. | | | 2/2/1996. |
| | 39 | | 5,643,550 | July 1, 1997 | Welt et al. | | | 9/27/1994 |
| | 47 | | 5,160,723 | November 3, 1991 | Welt et al. | | | 3/18/ 1991. |
| | | | | | | | | |
| | | | | | | | | |

## FOREIGN PATENT DOCUMENTS

| Exam Initial | No. | | Document No. | Date | Country | Class | Subclass | Translation Yes No |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

NY02:524633.3

Examiner Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office | Atty. Docket No. A33081-R 072771.0106 | Serial No. 09/633,034 |
|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** | Applicant Tsang *et al.* | |
| **(Use several sheets if necessary)** | Filing Date August 4, 2000 | Group 1642 |
| | Examiner Helms, L.R. | |

| Exam Initial | No. | | OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) |
|---|---|---|---|
| | 1 | | Chong, G., F. T. Lee, et al. (2005). "Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma." Clin Cancer Res 11(13): 4818-26. |
| | 2 | | Koppe, M. J., R. P. Bleichrodt, et al. (2005). "Radioimmunotherapy and colorectal cancer." Br J Surg 92(3): 264-276. |
| | 3 | | Mallegol, J., G. van Niel, et al. (2005). "Phenotypic and functional characterization of intestinal epithelial exosomes." Blood Cells Mol Dis 35(1): 11-16. |
| | 4 | | Scott, A. M., F. T. Lee, et al. (2005). "A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake." Clin Cancer Res 11(13): 4810-4817. |
| | 5 | | Deckert, P. M., W. G. Bornmann, et al. (2004). "Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine." Int J Oncol 24(5): 1289-95. |
| | 6 | | Joosten, C. E., L. S. Cohen, et al. (2004). "Glycosylation profiles of the human colorectal cancer A33 antigen naturally expressed in the human colorectal cancer cell line SW1222 and expressed as recombinant protein in different insect cell lines." Biotechnol Prog 20(4): 1273-9. |
| | 7 | | Deckert, P. M., C. Renner, et al. (2003). "A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy." Br J Cancer 88(6): 937-9. |
| | 8 | | Mao, Z., S. Song, et al. (2003). "Transcriptional regulation of A33 antigen expression by gut-enriched Kruppel like factor." Oncogene 22(28): 4434-43. |
| | 9 | | Welt et al., 2003, Phase I Study of Anticolon Cancer Humanized Antibody A331. Clinical Cancer Res. 9(4):1338-1346. |

NY02:524633.3

Examiner Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office | Atty. Docket No. A33081-R 072771.0106 | Serial No. 09/633,034 |
|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** (Use several sheets if necessary) | Applicant Tsang *et al.* | |
| | Filing Date August 4, 2000 | Group 1642 |
| | Examiner Helms, L.R. | |

| Exam Initial | No. | | OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) |
|---|---|---|---|
| | 10 | | Welt, S., G. Ritter, et al. (2003). "Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer." Clin Cancer Res 9(4): 1347-53. |
| | 13 | | Johnstone, C. N., S. J. White, et al. (2002). "Analysis of the regulation of the A33 antigen gene reveals intestine-specific mechanisms of gene expression." J Biol Chem 277(37): 34531-9. |
| | 14 | | Orlova, A., J. Hoglund, et al. (2002). "Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry." Cancer Biother Radiopharm 17(4): 385-96. |
| | 15 | | van Niel, G. and M. Heyman (2002). "The epithelial cell cytoskeleton and intracellular trafficking. II. Intestinal epithelial cell exosomes: perspectives on their structure and function." Am J Physiol Gastrointest Liver Physiol 283(2): G251-5. |
| | 16 | | Barendswaard, E. C., J. L. Humm, et al. (2001). "Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft." J Nucl Med 42(8): 1251-6. |
| | 17 | | Lee, F. T., A. Rigopoulos, et al. (2001). "Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts." Cancer Res 61(11): 4474-82. |
| | 18 | | Ritter, G., L. S. Cohen, et al. (2001). "Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33." Cancer Res 61(18): 6851-9. |
| | 19 | | van Niel, G., G. Raposo, et al. (2001). "Intestinal epithelial cells secrete exosome-like vesicles." Gastroenterology 121(2): 337-49. |
| | 20 | | Abud, H. E., C. N. Johnstone, et al. (2000). "The murine A33 antigen is expressed at two distinct sites during development, the ICM of the blastocyst and the intestinal epithelium." Mech Dev 98(1-2): 111-4. |

NY02:524633.3

Examiner Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office | Atty. Docket No. A33081-R 072771.0106 | Serial No. 09/633,034 |
|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** (Use several sheets if necessary) | Applicant Tsang *et al.* | |
| | Filing Date August 4, 2000 | Group 1642 |
| | Examiner Helms, L.R. | |

| Exam Initial | No. | | OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) |
|---|---|---|---|
| | 21 | | Deckert, P. M., A. Jungbluth, et al. (2000). "Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts." Int J Cancer 87(3): 382-90. |
| | 22 | | Johnstone, C. N., N. C. Tebbutt, et al. (2000). "Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells." Am J Physiol Gastrointest Liver Physiol 279(3): G500-10. |
| | 23 | | Rader, C., G. Ritter, et al. (2000). "The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies." J Biol Chem 275(18): 13668-76. |
| | 24 | | Ruan, S., J. A. O'Donoghue, et al. (2000). "Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam." J Nucl Med 41(11): 1905-12. |
| | 25 | | Sakamoto, J., H. Kojima, et al. (2000). "Organ-specific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibody-based imaging and treatment in gastrointestinal cancer." Cancer Chemother Pharmacol 46 Suppl: S27-32. |
| | 26 | | Barendswaard, E. C., J. A. O'Donoghue, et al. (1999). "131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft." J Nucl Med 40(10): 1764-8. |
| | 27 | | Miyazono, Y., Y. Kamogawa, et al. (1999). "Effect of B7.1-transfected human colon cancer cells on the induction of autologous tumour-specific cytotoxic T cells." J Gastroenterol Hepatol 14(10): 997-1003. |
| | 29 | | Barendswaard, E. C., A. M. Scott, et al. (1998). "Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice." Int J Oncol 12(1): 45-53. |
| | 30 | | Burgess, A. W. (1998). "Growth control mechanisms in normal and transformed intestinal cells." Philos Trans R Soc Lond B Biol Sci 353(1370): 903-9. |

NY02:524633.3

Examiner Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office | Atty. Docket No. A33081-R 072771.0106 | Serial No. 09/633,034 |
|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** (Use several sheets if necessary) | Applicant Tsang *et al.* | |
| | Filing Date August 4, 2000 | Group 1642 |
| | Examiner Helms, L.R. | |

| Exam Initial | No. | | OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) |
|---|---|---|---|
| | 31 | | Moritz, R. L., G. Ritter, et al. (1998). "Micro-sequencing strategies for the human A33 antigen, a novel surface glycoprotein of human gastrointestinal epithelium." J Chromatogr A 798(1-2): 91-101. |
| | 32 | | Tio, T. L. (1998). "Diagnosis and staging of esophageal carcinoma by endoscopic ultrasonography." Endoscopy 30 Suppl 1: A33-40. |
| | 34 | | Catimel, B., M. Nerrie, et al. (1997). "Kinetic analysis of the interaction between the monoclonal antibody A33 and its colonic epithelial antigen by the use of an optical biosensor. A comparison of immobilisation strategies." J Chromatogr A 776(1): 15-30. |
| | 35 | | Heath, J. K., S. J. White, et al. (1997). "The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily." Proc Natl Acad Sci U S A 94(2): 469-74. |
| | 36 | | Ji, H., R. L. Moritz, et al. (1997). "Electrophoretic analysis of the novel antigen for the gastrointestinal-specific monoclonal antibody, A33." Electrophoresis 18(3-4): 614-21. |
| | 37 | | Ritter, G., L. S. Cohen, et al. (1997). "Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium." Biochem Biophys Res Commun 236(3): 682-6. |
| | 38 | | Tschmelitsch, J., E. Barendswaard, et al. (1997). "Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil)." Cancer Res 57(11): 2181-6. |
| | 40 | | No Author listed. (1996). "MoAb A33 shows promise in targeting colon cancer for radioimmunotherapy." Oncology (Huntingt) 10(4): 553. |
| | 41 | | Antoniw, P., A. P. Farnsworth, et al. (1996). "Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM)." Br J Cancer 74(4): 513-24. |

NY02:524633.3

Examiner Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office | Atty. Docket No. A33081-R 072771.0106 | Serial No. 09/633,034 |
|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** (Use several sheets if necessary) | Applicant Tsang *et al.* | |
| | Filing Date August 4, 2000 | Group 1642 |
| | Examiner Helms, L.R. | |

| Exam Initial | No. | | OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) |
|---|---|---|---|
| | 42 | | Daghighian, F., E. Barendswaard, et al. (1996). "Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody." J Nucl Med 37(6): 1052-7. |
| | 43 | | Welt, S., A. M. Scott, et al. (1996). "Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer." J Clin Oncol 14(6): 1787-97. |
| | 44 | | King, D. J., P. Antoniw, et al. (1995). "Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy." Br J Cancer 72(6): 1364-72. |
| | 45 | | Scott, A. M., E. Rosa, et al. (1995). "In vivo imaging and specific targeting of P-glycoprotein expression in multidrug resistant nude mice xenografts with [125I]MRK-16 monoclonal antibody." Nucl Med Biol 22(4): 497-504. |
| | 46 | | Welt et al., 1994, Phase I/II Study of Iodine 131-Labeled Monoclonal Antibody A33 in Patients With Advanced Colon Cancer. J. Clin. Oncol. 12:1561-71 |
| | | | |
| | | | |

NY02:524633.3

Examiner Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.